Literature DB >> 16669853

Long-term and concentration-dependent beneficial effect of efavirenz on HDL-cholesterol in HIV-infected patients.

Sofia A Pereira1, Teresa Branco, Rita M Côrte-Real, Isabel Germano, Fátima Lampreia, Umbelina Caixas, Emília C Monteiro.   

Abstract

AIMS: To investigate the long-term effects of efavirenz on cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein (LDL-C) and triglycerides (TG).
METHODS: Thirty-four HIV-infected patients who commenced efavirenz therapy were monitored for 36 months.
RESULTS: In patients with baseline HDL-C<40 mg.dL-1 an increase in HDL-C from 31+/-1 mg.dL-1 to 44+/-2 mg.dL-1 (95% confidence interval 5.9, 21.9, P<0.01) was observed and remained throughout the follow-up period. Median efavirenz plasma concentration was 1.98 mg.L-1 and a direct correlation between percentage of HDL-C variation or TC/HDL-C ratio and efavirenz plasma concentrations was found.
CONCLUSIONS: There is evidence of a long-term and concentration-dependent beneficial effect of efavirenz on HDL-C in HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16669853      PMCID: PMC1885052          DOI: 10.1111/j.1365-2125.2006.02619.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients.

Authors:  Eugenia Negredo; Josep Ribalta; Raimon Ferré; Juliana Salazar; Celestino Rey-Joly; Guillem Sirera; Lluís Masana; Bonaventura Clotet
Journal:  AIDS       Date:  2004-03-26       Impact factor: 4.177

2.  Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.

Authors:  Jacques Fellay; Catia Marzolini; Emma R Meaden; David J Back; Thierry Buclin; Jean Philippe Chave; Laurent A Decosterd; Hansjakob Furrer; Milos Opravil; Giuseppe Pantaleo; Dorota Retelska; Lidia Ruiz; Alfred H Schinkel; Pietro Vernazza; Chin B Eap; Amalio Telenti
Journal:  Lancet       Date:  2002-01-05       Impact factor: 79.321

3.  The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism.

Authors:  Carlos Alonso-Villaverde; Blai Coll; Federico Gómez; Sandra Parra; Jordi Camps; Jorge Joven; Lluis Masana
Journal:  AIDS       Date:  2005-02-18       Impact factor: 4.177

4.  Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine.

Authors:  Cesar Fisac; Emilio Fumero; Manuel Crespo; Beatriz Roson; Elena Ferrer; Nuria Virgili; Esteban Ribera; Jose Maria Gatell; Daniel Podzamczer
Journal:  AIDS       Date:  2005-06-10       Impact factor: 4.177

5.  In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes.

Authors:  Khadija El Hadri; Martine Glorian; Christelle Monsempes; Marie-Noëlle Dieudonné; René Pecquery; Yves Giudicelli; Marise Andreani; Isabelle Dugail; Bruno Fève
Journal:  J Biol Chem       Date:  2004-01-13       Impact factor: 5.157

6.  Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.

Authors:  Frank van Leth; Prahpan Phanuphak; Erik Stroes; Brian Gazzard; Pedro Cahn; François Raffi; Robin Wood; Mark Bloch; Christine Katlama; John J P Kastelein; Mauro Schechter; Robert L Murphy; Andrzej Horban; David B Hall; Joep M A Lange; Peter Reiss
Journal:  PLoS Med       Date:  2004-10-19       Impact factor: 11.069

  6 in total
  6 in total

1.  Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients.

Authors:  S A Pereira; J R Batuca; U Caixas; T Branco; J Delgado-Alves; I Germano; F Lampreia; E C Monteiro
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

Review 2.  Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy.

Authors:  Emma Kaplan-Lewis; Judith A Aberg; Mikyung Lee
Journal:  Curr HIV/AIDS Rep       Date:  2016-10       Impact factor: 5.071

3.  Prospective plasma efavirenz concentration assessment in Chinese HIV-infected adults enrolled in a large multicentre study.

Authors:  F Guo; X Cheng; E Hsieh; X Du; Q Fu; W Peng; Y Li; X Song; J-P Routy; T Li
Journal:  HIV Med       Date:  2018-05-15       Impact factor: 3.180

4.  Human paraoxonase-1 activity is related to the number of CD4+ T-cells and is restored by antiretroviral therapy in HIV-1-infected individuals.

Authors:  Luciana Morganti Ferreira Maselli; Joel da Cunha; Eliana Battaggia Gutierrez; Raul Cavalcante Maranhão; Celso Spada; Sérgio Paulo Bydlowski
Journal:  Dis Markers       Date:  2014-02-27       Impact factor: 3.434

5.  Serum Lipid Profiles of Patients Taking Efavirenz-Based Antiretroviral Regimen Compared to Ritonavir-Boosted Atazanavir with an Optimized Background at Zewditu Memorial Hospital, Addis Ababa, Ethiopia.

Authors:  Abebe Muche Belete; Daniel Seifu; Menakath Menon; Wondwossen Amogne; Aster Shewa; Alemu Adela Tefera
Journal:  HIV AIDS (Auckl)       Date:  2021-02-19

6.  Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations.

Authors:  Phumla Zuleika Sinxadi; Helen Margaret McIlleron; Joel Alex Dave; Peter John Smith; Naomi Sharlene Levitt; David William Haas; Gary Maartens
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.